Stephen B. Williams, MD, MS, discusses a recent study evaluating costs of surgical treatments for bladder cancer.
In this interview, Stephen B. Williams, MD, MS, discusses findings from a recent Urology paper, Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care, for which he served as a study author. Williams is chief of urology and professor of urology and radiology at the University of Texas Medical Branch at Galveston.
More videos:
Dr. Ben Chew discusses kidney stones and metabolic syndrome
Dried cranberry powder shows promise in overactive bladder
Dr. Michael Albo discusses female urology training fellowships
FDA approves nivolumab plus cisplatin/gemcitabine in urothelial carcinoma
March 7th 2024The approval is based on data from the phase 3 CheckMate-901 trial, which demonstrated improved overall survival and progression-free survival with the nivolumab-combination therapy vs cisplatin/gemcitabine alone.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.